文献速递免疫规划

母体肺炎球菌和脑膜炎球菌抗体流行率及衰减:型特异性衰减率的荟萃分析

Prevalence and decay of maternal pneumococcal and meningococcal antibodies: A meta-analysis of type-specific decay rates.
PubMed 文献 · Vaccine · 2017-09-19

该荟萃分析利用来自14个国家临床试验的个体参与者血清学数据,估计了婴儿中母体抗荚膜肺炎球菌和脑膜炎球菌抗体的血清阳性率及型特异性半衰期;肺炎球菌抗体半衰期范围为38.7天至48.3天,总体半衰期为42.6天,脑膜炎球菌A群和C群半衰期分别为43.1天和39.8天;作者认为这些估计可用于建模建议的疫苗接种规划影响及考虑延迟启动的免疫程序。

要点

  • 母体肺炎球菌抗体血清阳性率以血清型14和19F最高(分别为92%和80%),血清型4和1最低(分别为30%和34%)。
  • 肺炎球菌抗体半衰期从血清型6B的38.7天(95%CI 36.6-41.0)到血清型5的48.3天(95%CI 46.7-50.2),总体为42.6天(95%CI 41.5-43.7)。
  • 脑膜炎球菌C群血清阳性率为13%(半衰期39.8天,95%CI 33.4-49.4),A群为43%(半衰期43.1天,95%CI 39.8-47.2)。

核心结论

  • 许多国家相当比例的婴儿具有针对肺炎球菌疫苗血清型的抗体,但具有母体获得的A群和C群脑膜炎球菌抗体的婴儿较少;被动获得的抗荚膜多糖抗体以约6周的半衰期衰减;这些估计可用于建模建议的疫苗接种规划影响及考虑延迟启动的免疫程序。

研究设计与样本

  • 从临床试验获取个体参与者血清学数据,纳入14个国家未接种脑膜炎球菌或肺炎球菌疫苗的婴儿,估计型特异性半衰期。

主要发现

  • 母体肺炎球菌抗体血清阳性率血清型14为92%、19F为80%、4为30%、1为34%。
  • 肺炎球菌抗体半衰期血清型6B为38.7天(95%CI 36.6-41.0),血清型5为48.3天(95%CI 46.7-50.2),总体为42.6天(95%CI 41.5-43.7)。
  • 血清阳性率在马里、尼日利亚、印度和菲律宾最高(均>65%),在捷克共和国和芬兰最低(均<45%)。
  • 脑膜炎球菌疫苗研究中,C群血清阳性率为13%(半衰期39.8天,95%CI 33.4-49.4),A群为43%(半衰期43.1天,95%CI 39.8-47.2)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: At the time of an infant's initial vaccination at age ∼2 to 3months, some infants already have maternal antibodies against vaccine antigens and these can suppress the immune response to vaccination. Modelling the effects of maternal antibody and the timing of infant doses on the antibody response to vaccination, requires estimates of the rate of maternal antibody decay. Decay rates are not well characterised in the medical literature. We investigated variation in the prevalence of maternal anti-capsular pneumococcal and meningococcal antibodies in infants in 14 countries, and estimated type-specific half-lives. METHODS: Individual participant serological data were obtained from clinical trials. Half-lives were estimated from antibody concentrations in infants who did not receive meningococcal or pneumococcal vaccines. RESULTS: The seroprevalence of maternal pneumococcal antibodies was highest for serotypes 14, and 19F (92% and 80% respectively) and lowest for serotypes 4 and 1 (30% and 34% respectively). Half-life estimates ranged from 38.7days (95% CI 36.6-41.0) for serotype 6B, to 48.3days (95% CI 46.7-50.2) for serotype 5. The overall half-life was 42.6days (95% CI 41.5-43.7). Seroprevalence was highest in Mali, Nigeria, India, and the Philippines, (all >65%) and lowest in the Czech Republic and Finland (both <45%). In studies of meningococcal vaccines, seroprevalence was 13% for group C (half-life 39.8days, 95% CI 33.4-49.4) and 43% for group A (half-life 43.1days 95% CI 39.8-47.2). CONCLUSION: Substantial proportions of infants in many countries have antibodies to vaccine serotypes of pneumococcus, however fewer infants have maternally acquired antibodies to groups A and C meningococcus. Passively-acquired antibodies to capsular polysaccharides decay with a half-life of approximately 6weeks. These estimates are useful for modelling the impact of proposed vaccination programmes, and consideration of schedules with a delayed start.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Voysey M, Pollard AJ, Sadarangani M, et al. Prevalence and decay of maternal pneumococcal and meningococcal antibodies: A meta-analysis of type-specific decay rates. Vaccine. 2017. PMID: 28935471. doi:10.1016/j.vaccine.2017.09.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。